Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence United Kingdom Pricing Strategies

UK Paracetamol Prices Treble Amid Coronavirus Demand

Pricewatch UK – March 2020

  • Data

Executive Summary

Average UK trade prices for paracetamol more than trebled in March as the coronavirus outbreak took hold, while the antiviral valaciclovir saw an average increase of over 300%.

You may also be interested in...



Exemestane Prices Tumble As UK Sees Reductions

Exemestane 25mg tablets saw their average UK trade price drop by a third in November, according to the latest figures from WaveData.

Moxonidine Rises Ramp Up In August

Moxonidine topped our table of Biggest Risers for the second month in a row, as UK prices that had doubled in July accelerated even more rapidly in August.

UK Aspirin Prices Double In June

Aspirin led the generics with the fastest-rising UK prices in June, according to the latest figures from WaveData.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Tags:
Market Intelligence United Kingdom Pricing Strategies
Latest Headlines

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars

Fresenius Kabi Gets Ready To Launch Europe’s First Tocilizumab Rival

BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar

See All
UsernamePublicRestriction

Register

GB149798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By